Advertisement

Picture Fairtec GmbH We Optimise the ROI of Your Event 600x60px
Document › Details

Pierre Fabre S.A.. (11/2/15). "Press Release: Pierre Fabre Joins the IQ Consortium, an Organization Bringing together Pharmaceutical and Biotech Companies from All Over the World". Castres.

Organisations Organisation Pierre Fabre Médicament S.A.
  Group Pierre Fabre (Group)
  Organisation 2 IQ Consortium (International Consortium for Innovation and Quality in Pharmaceutical Development)
Products Product quality management services
  Product 2 pharmaceutical
Index term Index term IQ Consortium–Pierre Fabre: quality management, 201511 Pierre Fabre becomes member of IQ Consortium
Person Person Audoly, Laurent (Kymera Thearapeutics 201710– CEO before Pierre Fabre SVP RnD before Pieris 201006–2010307 CSO)
     


> The IQ Consortium promotes science and technology by facilitating partnerships between its members

> Pierre Fabre Médicament’s research teams seek to broaden and share their expertise


Pierre Fabre Médicament joined the International Consortium for Innovation and Quality in Pharmaceutical Development (IQ), a scientific non-profit organization bringing together 39 Members* (pharmaceutical and biotechnology companies from around the world). The IQ Consortium aims at helping its members develop transformative therapeutic solutions by encouraging them to form scientific and technological partnerships, and build relationships with international regulatory authorities (FDA, EMA, ANSM, MHRA..).

Being a part of the IQ Consortium’s network will allow Pierre Fabre Médicament to prepare for scientific and regulatory changes in the R&D field, and to implement and shape R&D best practices, while benefitting from the experience of other members.

In keeping with this spirit of scientific excellence and cross-fertilization of ideas, Pierre Fabre’s research teams will participate in many of the Consortium’s committees, including the ones dealing with “clinical pharmacology,” “drug metabolism,” “drug safety,” “antibody-drug conjugates,” “3Rs-alternative methods,” “pharmacokinetics and pharmacodynamics,” and “tissue distribution imaging.”

As a member of the IQ Consortium, the Pierre Fabre Group also intends to build relationships with university and public research institutes worldwide, and to expand its international network.

“We are pleased to become a member of the IQ Consortium, which brings together high-quality scientific and medical players from all over the word. The collaborative and international approach developed by the Consortium is fully consistent with the innovation model Pierre Fabre intends to promote in the coming years,” welcomed Pr. Laurent Audoly, Global Head R&D at Pierre Fabre Médicament.


* AbbVie, Agios, Alexion Pharmaceuticals, Alkermes, Allergan, Amgen Inc, Astellas Pharma US LLC, AstraZeneca Pharmaceuticals, Bayer Health Care, Baxter Healthcare Corporation, Biogen, Blueprint Medicines, Boehringer Ingelheim, Bristol Myers Squibb Compagny, Celgene Corporation, Daiichi Sankyo, Eisaï Inc, Eli Lily and Company, EMD Serono, Endo Pharmaceuticals, Genentech, Gilead Sciences, GlaxoSmithKline, Incyte Corporation, Infinity Pharmaceuticals, Johnson & Johnson, Kythera Biopharmaceuticals, Merck & Co., Novartis, Pierre Fabre, Pfizer, Roche, Sanofi, Seattle Genetics, Sunovion, Otsuka Pharmaceutical Co., Takeda, Teva Pharmaceutical, Vertex Inc.


About Pierre Fabre

Pierre Fabre is the 3rd largest French pharmaceutical group and the 2nd largest dermo-cosmetics laboratory in the world. In 2014, its sales reached €2.1 Billion, with revenues in dermo-cosmetics accounting for 55% and international sales for 55%. Founded and its headquarters still based in the South-west of France, Pierre Fabre currently has branches in 44 countries and distribution agreements in over 130 countries.

Covering a continuum of healthcare products, from prescription drugs and consumer health care products (family care, oral care, natural health) to dermo-cosmetics, Pierre Fabre Laboratories employ over 10,000 people worldwide. In 2014, Pierre Fabre dedicated more than 17% of its drug revenues to R&D.

With brands such as Eau Thermale Avène, Klorane, Ducray, René Furterer, A-Derma, Galénic, Naturactive, Elgydium, Eludril or Drill, Pierre Fabre Laboratories are market leaders when it comes to skin, hair and oral care products distributed in the French pharmacy channel. Eau Thermale Avène is marketed worldwide, and is the leading dermo-cosmetics brand sold in Europe, Japan and China. In oncology, Pierre Fabre achieves 90% of its revenues outside of its home country.

Through the Pierre Fabre Participations holding company, the Pierre Fabre Foundation, a government-recognized public-interest foundation, owns 86% of Pierre Fabre Laboratories. Remaining shares are owned by company employees, amounting to 7,3 %, and through treasury stock.

The French certification group AFNOR has audited Pierre Fabre Laboratories for its corporate social responsibility (CSR) performance at advanced level (AFAQ 26 000)

To find out more, please visit www.pierre-fabre.com


About the IQ Consortium

The International Consortium for Innovation and Quality in Pharmaceutical Development (IQ, www.iqconsortium.org) is a technically-focused organization of pharmaceutical and biotechnology companies with a mission of advancing science and technology to augment the capability of member companies to develop transformational solutions that benefit patients, regulators and the broader R&D community. IQ provides a sustained forum for the exchange of ideas within and across technical disciplines in these industries. The Consortium is leading initiatives in the areas of chemistry, manufacturing and control; preclinical safety; drug metabolism; clinical pharmacology; quality; and the reduction, refinement, and replacement of animal testing. As part of these initiatives, which are managed by Leadership Groups and Working Groups, members lead and participate in collaborative research, industry surveys and benchmarking exercises. IQ is also partnering with governmental bodies, other trade groups, and academic researchers. Through publications, scientific conferences, workshops and roundtables, the Consortium shares the results of its work and facilitates constructive scientific exchange.


________________________________________

Contacts:

Valérie Roucoules
Pierre Fabre
Deputy Director Media Relations
Tel.: +33 1 49 10 83 84
Email: valerie.roucoules@pierre-fabre.com

ALIZE RP
Caroline Carmagnol/Florence Portejoie
and Wendy Rigal
Tel.: + 33 1 44 54 36 66
Email: pierre-fabre@alizerp.com

   
Record changed: 2018-05-15

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany iito 600x60px

More documents for Pierre Fabre (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px




» top